Elanco Animal Health (ELAN) Price & Analysis
ELAN Stock Chart & Stats
- Day’s Range
- MXN 380.00 - MXN 380.00
- 52-Week Range
- MXN 297.51 - MXN 399.50
- Previous Close
- MXN 380.00
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 216.44B
- Enterprise Value
- MXN 15.84B
- Total Cash (Recent Filing)
- MXN 530.00M
- Total Debt (Recent Filing)
- MXN 3.92B
- Price to Earnings (P/E)
- ―
- Beta
- -0.13
- Next Earnings
- Nov 06, 2026
- EPS Estimate
- 3.81
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Broad-based organic growth, supported by volume and pricing, indicates continued demand for Elanco’s animal-health portfolio. Raised full-year guidance provides evidence that momentum is expected to persist beyond one quarter, strengthening the company’s medium-term revenue foundation.
Innovation Portfolio
A growing contribution from newer products can refresh the portfolio and reduce reliance on mature brands. Zenrelia and Credelio Quattro are showing measurable adoption, reorder activity, and market-share gains, supporting durable commercial momentum and future product-led growth.
Cash Generation And Deleveraging
Positive free cash flow despite negative net income gives Elanco resources to fund research, launches, debt service, and reinvestment. Combined with lower net leverage, this improves financial flexibility and supports a more resilient capital structure over the next several quarters.
Bears Say
Persistent Net Losses
Revenue and gross-margin improvement have not yet translated into consistent bottom-line profitability. Continued negative net margin and ROE limit internal earnings accumulation, reduce returns on the equity base, and leave execution on product growth and cost control especially important.
Meaningful Leverage
Leverage has improved from 2023 but remains material, which can restrict financial flexibility while profitability is still inconsistent. Debt obligations may compete with investment in innovation and launches, making continued free-cash-flow generation and deleveraging important to long-term resilience.
Launch Capacity And Cost Pressure
Demand for Befrena is exceeding initial expectations, but constrained supply delays the product’s ability to contribute fully to growth. At the same time, elevated launch and R&D spending can pressure margins before commercial scale and productivity savings offset those investments.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
What is Elanco Animal Health’s market cap?
When is Elanco Animal Health’s upcoming earnings report date?
How were Elanco Animal Health’s earnings last quarter?
Is Elanco Animal Health overvalued?
Does Elanco Animal Health pay dividends?
What is Elanco Animal Health’s EPS estimate?
How many shares outstanding does Elanco Animal Health have?
What happened to Elanco Animal Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Elanco Animal Health?
What is the TipRanks Smart Score and how is it calculated?
Elanco Animal Health Stock Smart Score
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Jeffrey N. Simmons
- Employees
- 9,650
- Website
- www.elanco.com
- Address
- 450 Elanco Circle, Indianapolis, IN, 46221, US
Elanco Animal Health (ELAN) Earnings & Revenues
ELAN Company Deck
ELAN Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.
View all MX:ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 0 | 8 |
| Technical Analysis | 1 | 0 | 2 |
| Moving Averages | 6 | 0 | 6 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| PAHCPhibro Animal Health |